沙库巴曲缬沙坦钠片对心力衰竭合并心房颤动患者心功能及预后的影响

Effect of Sacubitril Valsartan Sodium Tablets on cardiac function and prognosis in patients with heart failure complicated with atrial fibrillation

目的探讨沙库巴曲缬沙坦钠片对心力衰竭合并心房颤动患者心功能及预后的影响。方法选取2020年1月至2021年12月新余市人民医院收治的82例心力衰竭合并心房颤动患者作为研究对象,按随机数字表法将其分为治疗组(42例)与对照组(40例),对照组患者采用盐酸贝那普利治疗,治疗组患者采用沙库巴曲缬沙坦钠片治疗。比较两组患者的临床疗效、6 min步行试验(6MWT)结果、N端脑钠肽前体(NT-ProBNP)水平、心脏超声指标、不良事件(再入院及心血管死亡)发生率及不良反应发生率。结果治疗组的总有效率(92.86%)高于对照组(75.00%),差异有统计学意义(P<0.05);治疗后,治疗组的6MWT长于对照组,NT-ProBNP水平低于对照组,差异有统计学意义(P<0.05);治疗后,治疗组的左室射血分数(LVEF)高于对照组,左心房内径(LA)、左室舒张末内径(LVEDD)及舒张早期二尖瓣血流速度与舒张早期二尖瓣环运动速度的比值(E/e')均低于对照组,差异有统计学意义(P<0.05);治疗组的不良事件发生率(7.14%)低于对照组(27.50%),差异有统计学意义(P<0.05);两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦钠片能有效改善心力衰竭合并心房颤动患者的心功能及心房颤动状态,恢复心脏功能指标,同时还能降低不良事件发生率,改善患者预后。

Objective To explore the effect of Sacubitril Valsartan Sodium Tablets on cardiac function and prognosis in patients with heart failure complicated with atrial fibrillation.Methods A total of 82 patients with heart failure complicated with atrial fibrillation admitted to Xinyu People's Hospital from January 2020 to December 2021 were selected as the research objects.They were divided into treatment group(42 cases)and control group(40 cases)according to the random number table method.The control group was treated with Benazepril Hydrochloride,and the treatment group was treated with Sacubitril Valsartan Sodium Tablets.The clinical efficacy,6-minute walking test(6MWT)results,N-terminal pro-brain natriuretic peptide(NT-ProBNP)levels,cardiac ultrasound indicators,incidence of adverse events(readmission and cardiovascular death)and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the treatment group(92.86%)was higher than that of the control group(75.00%),and the difference was statistically significant(P<0.05).After treatment,the 6MWT of the treatment group was longer than that of the control group,and the NT-ProBNP level was lower than that of the control group,and the differences were statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of the treatment group was higher than that of the control group,and the left atrial diameter(LA),left ventricular end-diastolic diameter(LVEDD)and the ratio of early diastolic mitral flow velocity to early diastolic mitral annular velocity(E/e')were lower than those of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse events in the treatment group(7.14%)was lower than that in the control group(27.50%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacubitril Valsartan Sodium Tablets can effectively improve the cardiac function and atrial fibrillation state of patients with heart failure complicated with atrial fibrillation,restore cardiac function indexes,reduce the incidence of adverse events,and improve the prognosis of patients.